Renascience Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	107	132	194	100	139	209
Revenue Growth (YoY)	-23.02%	-31.96%	94.00%	-28.06%	-33.49%	190.28%
Cost of Revenue	5	4	29	-	59	29
Gross Profit	102	128	165	100	80	180
Selling, General & Admin	248	159	167	185	193	265
Research & Development	132	132	236	235	82	-
Other Operating Expenses	16	16	13	13	13	-
Operating Expenses	396	307	417	434	291	265
Operating Income	-294	-179	-252	-334	-211	-85
Interest Expense	-	-	-	-	-5	-7
Currency Exchange Gain (Loss)	-1	-1	-	-	-	1
Other Non Operating Income (Expenses)	38	1	-1	-	-26	-
EBT Excluding Unusual Items	-256	-179	-253	-334	-242	-91
Asset Writedown	-1	-1	-4	-	-11	-
Other Unusual Items	-	323	-	-	-	-9
Pretax Income	-257	143	-257	-334	-253	-100
Income Tax Expense	2	30	1	1	1	-
Net Income	-259	113	-258	-335	-254	-100
Net Income to Common	-259	113	-258	-335	-254	-100
Shares Outstanding (Basic)	13	13	13	13	11	10
Shares Outstanding (Diluted)	13	13	13	13	11	10
Shares Change (YoY)	0.10%	-	-	11.61%	15.99%	0.00%
EPS (Basic)	-20.35	8.89	-20.30	-26.35	-22.30	-10.18
EPS (Diluted)	-20.35	8.89	-20.30	-26.35	-22.30	-10.18
Free Cash Flow	-	-176	-231	-286	-231	-
Free Cash Flow Per Share	-	-13.85	-18.17	-22.50	-20.28	-
Gross Margin	95.33%	96.97%	85.05%	100.00%	57.55%	86.12%
Operating Margin	-274.77%	-135.61%	-129.90%	-334.00%	-151.80%	-40.67%
Profit Margin	-242.06%	85.61%	-132.99%	-335.00%	-182.73%	-47.85%
Free Cash Flow Margin	-	-133.33%	-119.07%	-286.00%	-166.19%	-
EBITDA	-	-178	-251	-333	-208	-
EBITDA Margin	-	-134.85%	-129.38%	-	-149.64%	-
D&A For EBITDA	-	1	1	1	3	-
EBIT	-294	-179	-252	-334	-211	-85
EBIT Margin	-274.77%	-135.61%	-129.90%	-	-151.80%	-40.67%
Effective Tax Rate	-	20.98%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.